A drug candidate developed by Golden Biotechnology Corp is to enter phase 2 clinical trials patients in the US for treatment of severely ill COVID-19, pending authorization by the authorities, the Taiwanese drugmaker said.
The drug, called antroquinonol, is undergoing phase 2 clinical trials in the US, Peru and Argentina, where 174 hospital patients with mild to moderate COVID-19 symptoms are enrolled in the double-blind placebo study, the company said in statement on Wednesday last week.
Preliminary results of the phase 2 trials in the US were commended by an independent data monitoring committee assigned to the trials by the US